Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms.
Published in the Journal of Alzheimer’s Disease, the study found that, when compared to Black and Asian patients, white and Hispanic individuals with Alzheimer’s disease and/or related dementia disorders were more likely to be prescribed central nervous system (CNS) active drugs.
These include antidepressants, antipsychotics, and anticonvulsants, even though such drugs have been associated with cardiovascular events, hospitalisation, and on occasion, death. The majority of those exhibiting behavioural and psychological symptoms of dementia used a CNS drug, largely antidepressants. Even so, 67.6% of Hispanic individuals and 66% of white individuals were prescribed CNS drugs compared with 58.6% of Black patients and 54.5% of Asian patients. The study examined data from Medicare claims for those diagnosed with dementia from 2017 to 2019. This timeframe was taken before the onset of the COVID-19 pandemic, when the pandemic disrupted the US healthcare system.
Study lead author Johanna A Thunell, research scientist at USC Schaeffer Center, commented “The open question remains: are there actually higher rates of, say, depression among white people with dementia? Or are there cultural or other barriers that are keeping Black and Asian people with dementia from getting a diagnosis and potential treatment?”
Substantial differences in the type of drugs prescribed for different ethnic groups were revealed. Geoffry Joyce, director of Health Policy at the USC Schaeffer Center, stated “We also found substantial differences in who was taking individual drugs classes. For example, while white people were most likely to take antidepressants, American Indian and Alaska Natives had the highest rates of opioid prescriptions.” Opioids are highly addictive and have been at the centre of a continuing health crisis in the US.
Non-white people were also suggested to be underdiagnosed for treatable symptoms of dementia. A previous study by the USC Schaeffer Center found that Black and Hispanic patients more likely to have a late diagnosis or none at all. Such racial and ethnic differences in dementia diagnosis and care can have devastating impacts on the prognosis for these patients.
“We’re finding high levels of diagnoses of behavioural symptoms and use of drugs among these groups who are potentially vulnerable to these types of negative side effects,” commented Thunell. “There are certainly benefits to getting a diagnosis so that you can get some form of treatment – even if it’s non-pharmacological – and we aren’t seeing as high of rates of diagnoses in non-white people. This could present challenges for persons with dementia and their caregivers.”
Source:
USC study reveals racial disparities in diagnosis and drug use for dementia symptoms [Accessed May 14, 2024] https://www.eurekalert.org/news-releases/1044520
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb... -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News Pharma giants battle over COVID-19 patents in London courts
Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccin...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance